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The present paper provides an insight into the amyloid fibril formation by the apolipoprotein A-I 
N-terminal fragment in the presence of the oxidized phospholipids (oxPLs). Using Thioflavin T 
assay, the kinetic parameters of the protein fibrillization have been revealed. The novelty of the 
results obtained is as follows: i) the effects of the oxPLs varied with the lipid structure, 
concentration and the type of lipid assemblies; ii) PazePC micelles completely inhibited protein 
fibrillization; iii) a model for the association between the 1-83/G26R and POPC/PazePC bilayer 
has been suggested. 
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Abstract 
The effects of the oxidized phospholipids (oxPLs) on amyloid fibril formation by the 
apolipoprotein A-I variant 1-83/G26R have been investigated using Thioflavin T fluorescence 
assay. All types of the PoxnoPC assemblies (premicellar aggregates, micelles, lipid bilayer 
vesicles) induced the enhancement the 1-83/G26R fibrillization, although PazePC micelles 
completely prevented protein aggregation at low protein-to-lipid molar ratios. Furthermore, 1-
83/G26R fibrillization in the presence of the oxPLs was accompanied by the retardation of 
amyloid nucleation and elongation. Notably, the ability of PazePC to inhibit the formation of 1-
83/G26R fibrils was explained by the protein-lipid- electrostatic interactions, stabilizing the α-
helical structure of membrane/micelle-associated 1-83/G26R.  
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1. Introduction 
The oxidative stress is known to play a critical role in a wide variety of pathological states 
including the amyloid disorders, such as Alzheimer’s (AD), Parkinson’s (PD), Creutzfeldt–Jakob 
diseases (CJD), systemic amyloidosis (SA), etc. Furthermore, the damage of proteins, lipids and 
DNA by reactive oxygen species (ROS) precede the appearance of a major hallmark of these 
pathologies, amyloid fibril formation by specific proteins, Aβ peptide (AD), α-synuclein (PD), 
prion protein (CJD), lysozyme (SA), etc. [1-4]. To exemplify, Aβ peptide interactions with 
transition metal ions (viz. iron, copper, zinc, whose levels are elevated in AD brain), has been 
shown to result in ROS production followed by the enhanced Aβ aggregation [1,5]. The 
increased oxidative environment of dopaminergic neurons has been reported to induce α-
synuclein fibrillization and mitochondria damage in neurons, the processes being involved in the 
etiology of PD [6]. The lysozyme oxidation promoted the amyloid fibril formation in vitro, etc. 
[4,7]. 
Apolipoprotein A-I (apoA-I) is the main component of the plasma high density lipoproteins 
(HDL) involved in the two main processes: i) transferring the excess of cholesterol to the liver 
(reverse cholesterol transport) [8]; and ii) mediating the antioxidative processes in the low 
density lipoproteins (LDL) [9,10]. The HDL oxidation by myeloperoxidase in patients with 
established atherosclerosis has been demonstrated to limit their ability to participate in the 
reverse cholesterol transport [11]. Furthermore, the oxidation of methionine residues of apoA-I 
and genetic mutations, particularly, Iowa mutation (G26R) resulted in the amyloid fibril 
formation, associated with low HDL level and hereditary amyloidosis [12,13]. 
Protein amyloidogenesis has been proved to be a membrane-associated process, with lipid 
bilayer acting as a matrix which favours the aggregation-competent conformation of the 
polypeptide chain, interfacial accumulation and specific orientation of membrane-bound proteins 
[14,15]. Of great interest in this context is the modulation of amyloid fibril formation by the 
oxidatively damaged membranes, possessing the extended lipid conformation, altered polarity 
profile, lowered energy barrier for lipid flip-flop, etc. [16,17]. For instance, the fibrillization of 
Aβ peptide and gelsolin, was enhanced in the presence of the oxPLs presumably due to the 
Schiff-base or β-sheet formation, respectively, followed by the protein aggregation [18,19]. The 
above studies reported protein fibrillization in the presence of two stable lipid oxidation 
products, namely 1-palmitoyl-2-azelaoyl-sn-glycero-3-phosphocholine (PazePC) and 1-
palmitoyl-2-(9'-oxononanoyl)-sn-glycero-3-phosphocholine (PoxnoPC). According to the 
molecular dynamic simulations, in the lipid bilayer the polar chain of PazePC is oriented in such 
a manner that the carboxyl group is located in the aqueous phase, while the carbonyl group of 
PoxnoPC resides in the glycerol backbone region [20]. The fact that the reactive groups of these 
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compounds are localized near the membrane surface could explain the observed pronounced 
effects of the oxPLs on the amyloid fibril formation. However, the precise mechanisms 
underlying the such effects remain largely unknown. Some metal oxides have been reported to 
inhibit amyloid fibril formation, suggesting the complex nature of oxidative modification of the 
protein structure [21]. Our recent studies showed that the lipid bilayers containing PoxnoPC, 
trigger insulin fibrillization at physiological pH, while those containing PazePC, inhibit this 
process as compared to the POPC bilayers [22]. Interestingly, the oxPLs dispersions induced a 
more pronounced enhancement of the lysozyme amyloid formation than liposomes, being 
accompanied by the increase of the lag time [22]. The finding that the the oxidized phospholipids 
can not only promote, but also suppress amyloid nucleation and growth, render them potential 
candidates for anti-amyloid agents. To gain deeper insight into the effects of PazePC and 
PoxnoPC on the amyloid formation, we further extended our investigations to the N-terminal 1-
83 fragment of human apolipoprotein A-I (1-83) and its aggregation-competent variant G26R (1-
83/G26R) [12]. More specifically, the present study was aimed at monitoring the kinetics of 1-
83/G26R fibrillization in vitro using Thioflavin T assay and testing the ability of the oxPLs to 
inhibit the amyloid growth. Our goals were: i) to estimate the kinetic parameters of the protein 
aggregation in the presence of lipids; ii) to compare the effects of the oxPLs-containing 
liposomes, micelles and dispersions on 1-83 and 1-83/G26R fibrillization; iii) to uncover the role 
of the G26R mutation in the oxPLs-mediated amyloidogenesis of the N-terminal 1-83 fragment 
of apolipoprotein A-I. 
 
2. Materials and methods  
Materials 
The N-terminal 1-83 fragment of human apolipoprotein A-I (1-83) and its variant G26R (1-
83/G26R) were expressed and purified as described previously [12,23]. Thioflavin T was from 
Molecular Probes (Oregon, USA). The dye stock solution was prepared in Tris-HCl buffer (150 
mM NaCl, 0.01 % NaN3, pH 7.4). ThT concentration was determined spectrophotometrically 
using the extinction coefficient 412 23800   M
-1
cm
-1
. 1-palmitoyl-2-azelaoyl-sn-glycero-3-
phosphocholine (PazePC), 1-palmitoyl-2-(9'-oxononanoyl)-sn-glycero-3-phosphocholine 
(PoxnoPC), and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) lipids were from 
Avanti Polar Lipids (Alabaster, AL). The structures of the used lipids are shown in Fig. 1. 
Preparation of lipid dispersions, micelles and vesicles 
Lipid dispersions and vesicles were obtained as described previously [24]. Briefly, the 
sonication was employed to obtain lipid dispersions (below and above critical micelle 
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concentration). The 100-nm lipid vesicles from POPC and its mixtures with PazePC (20 mol%) 
or PoxnoPC (20 mol%) were prepared by the extrusion technique. 
The kinetics of amyloid formation monitored by Thioflavin T assay 
The apoA-I N-terminal fragments 1-83 and 1-83/G26R were freshly dialyzed from 6 M 
guanidine hydrochloride solution into 10 mM Tris buffer (150 mM NaCl, 0.01 % NaN3, pH 7.4) 
before use. The kinetics of amyloid formation by the 1-83 and 1-83/G26R fragments was 
monitored by Thioflavin T assay. Specifically, 96-well plates (Frickenhausen, Germany) filled 
with the dye (10 µM), proteins (5 µM) and lipids (0 – control samples, 0.5, 5 or 50 µM) were 
loaded into a fluorescence microplate reader (SPECTRAFluor Plus, Tecan, Austria), heated to 37 
ºC and incubated under constant shaking up to several days. ThT fluorescence was recorded over 
time at 485 nm (10 nm bandpass filter) using excitation at 430 nm (35 nm bandpass filter). 
The quantitative characteristics of the fibrillization process were obtained by approximating 
the time ( t ) dependence of ThT fluorescence intensity at 485 nm ( F ) with the sigmoidal curve 
[12]: 
max 0
0
1 exp[ ( )]m
F F
F F
k t t

 
 
,          (1) 
where 0F  and maxF  are ThT fluorescence intensities in the free form and in the presence of 
protein after the saturation has been reached, respectively; k  is the apparent rate constant for the 
fibril growth; mt  is the time needed to reach 50% of maximal fluorescence. The lag time was 
calculated as: 2 /mt k .  
 
3. Results and discussion 
As seen in Fig. 2, the effect of the oxidized phospholipids on the fibrillization of 1-83/G26R 
varies with the lipid structure and concentration. Specifically, the most pronounced (up to ~3 
times) increase in the maximum Thioflavin T fluorescence 
maxF , which is proportional to the 
extent of fibril formation, was observed at the protein-to-lipid molar ratio 1:1 (Table 1) [25]. 
Likewise, above the critical micelle concentration (at lipid concentration 50 µM), the lowest 
maxF  values were recovered [26]. The fact that below the CMC Thioflavin T fluorescence was 
proportional to the lipid concentration, while above the CMC it substantially decreased, agree 
with the results reported by Mahalka et al. for the fibrillization of gelsolin fragments, induced by 
PoxnoPC [27]. Furthermore, this tendency was also observed for the insulin fibrillization in the 
presence of PazePC [22]. Notably, the opposite effects of the PoxnoPC and PazePC on the 1-
83/G26R aggregation at the lipid concentrations 5 µM and 50 µM could be attributed to the 
different mechanisms of the protein interaction with premicellar aggregates and micelles [27]. 
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Next, both oxPLs slowed down the 1-83/G26R nucleation, resulting in a substantial increase 
in the lag time (up to 3-fold) and decrease in the fibrillization rate k  (up to 5-fold), as compared 
to the control samples (Table 1). Similarly, the extension of the lag time was observed for 
FtG179–194 gelsolin fragment in the presence of PoxnoPC [27]. These results suggest the ability of 
the examined oxPLs to form stable complexes with apoA-I N-terminal fragment, hampering the 
formation of amyloid nuclei and stabilizing the protein oligomers [28]. 
Furthermore, at the protein-to-lipid molar ratio 1:1, PazePC induced less pronounced 
enhancement of the 1-83/G26R fibrillization than PoxnoPC. The former also exerted inhibiting 
effect on the protein fibrillization at the smaller or greater protein-to-lipid molar ratios (Table 1). 
Specifically, no change in ThT fluorescence was observed upon the 1-83/G26R incubation in the 
presence of 50 µM PazePC, indicating that lipid micelles prevent the protein fibrillization. 
Similarly, Mahalka et al. demonstrated that PazePC did not have a noticeable influence on the 
fibrillization of FtG179–194 gelsolin fragment, while PoxnoPC promoted the peptide aggregation 
[27]. In turn, PazePC enhanced the amyloid formation by the lysozyme and insulin, showing a 
more significant effect on the insulin aggregation than PoxnoPC [22]. This may result from the 
specific interactions of the carboxyl group of PazePC with insulin, inducing its partial 
denaturation and transition into the aggregation-prone conformation [22]. As the G26R mutation 
promotes amyloid fibril formation through the destabilization of the α-helical structure of the 1-
83/G26R fragment associated with lipid bilayer, the 1-83/G26R binding to PazePC micelles 
could induce the opposite effect, preventing the protein aggregation [11]. 
As seen in Fig. 3, the lag time of amyloid fibril formation by 1-83/G26R in the absence of 
lipids was about 3 times smaller, and the fibrillization rate was 6 times greater, as compared to 
the correspondent values for the 1-83 aggregation. These results are in harmony with the data of 
Adachi et al., suggesting that G26R mutation enhanced the amyloid fibril formation [11]. 
Furthermore, the apparent rate constant for the 1-83 fibril growth in the presence of the oxPLs 
was twice than its control value, the lag time was increased 2-fold, and the fibrillization extent 
was reduced (Table 1). Thus, similarly to the 1-83/G26R, the 1-83 forms a smaller number of 
fibrils in the presence of PazePC micelles. 
In the following, the effect of lipid vesicles composed of POPC and its mixtures with the 
oxPLs on the 1-83/G26R amyloid fibril formation has been evaluated. As seen in Fig. 4 and 
Table 1, the addition of liposomes to the protein solution induced ~2-fold increase of the maxF , 
~3–5-fold decrease of the k  value, and ~9–12-fold extension of the lag time. This tendency is in 
good agreement with the previously reported data obtained for FtG179–194 gelsolin fragment and 
insulin [22,27]. Specifically, PoxnoPC and PazePC incorporated into the liposomal membranes 
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slowed down the kinetics of amyloid fibril formation, as compared to the control samples and 
lipid dispersions [22,27]. 
Furthermore, the effects of POPC, POPC/PazePC(20 mol%) and POPC/PoxnoPC(20 mol%) 
on the 1-83/G26R aggregation did not vary significantly, although inclusion of PazePC into 
POPC bilayer resulted in the ~40% decrease in the fibrillization extent, as compared to the neat 
POPC liposomes (Table 1). Notably, the fact that PazePC micelles prevented amyloid fibril 
formation by the apoA-I amyloidogenic fragment at the low lipid-to-protein weight ratio ~ 0.8 
(Fig. 2), while POPC/PazePC (20 mol%) liposomes slowed down the kinetics of the protein 
aggregation (Fig. 4), suggest that the observed effects are governed by specific PazePC-1-
83/G26R interactions with the lipid bilayers or micelles. These results, together with those 
reported for FtG179–194 gelsolin fragment, highlight a critical role of PazePC in inhibiting the 
amyloid fibril formation by the short (unstructured) peptides [27], although this lipid seems to 
induce misfolding and aggregation of the full-length proteins, like lysozyme or insulin, more 
effectively than PoxnoPC [22]. Interestingly, the oxPLs have been found to accelerate the 
amyloid nucleation, presumably due to the perturbation of the membrane structure and dynamics 
by the oxidized lipid tails [29].  
Recently, Saito et al. have reported the enhancement of the 1-83/G26R aggregation on 
POPC membranes produced by the G26R amyloidogenic mutation [25]. In contrast, no ThT 
fluorescence response was observed in the case of 1-83 at the lipid-to-protein weight ratio ~ 30. 
Our study indicates that the 1-83/G26R still retains the ability to form amyloid fibrils in the 
presence of vesicles containing the oxPLs at the lipid-to-protein weight ratio ~ 31 (Fig. 4). It can 
be assumed that there exist the α-helixes formed by the unstructured 1-83/G26R on the 
membrane surface, which are destabilized regardless of the presence of PazePC [11,25]. Such a 
destabilization induced by the G26R mutation promotes further transformation of the helixes into 
the β-sheets, followed by the amyloid fibril formation on the membrane surface, being a 
common mechanism for the natively unstructured proteins and peptides involved in amyloid 
pathologies [30–32].  
Finally, in order to explain the decrease of the 1-83/G26R fibrillization extent induced by 
the POPC/PazePC (20 mol%) vesicles (micelles), a model for the association between the 1-
83/G26R and POPC/PazePC bilayer has been suggested (Fig. 5). According to this model, the 
nonpolar faces of the amphipathic helixes of the ApoA-I N-terminal fragment, interact with the 
lipid bilayer while their polar faces are in contact with the aqueous phase [33,34]. The two 
panels in Fig. 5 are the helical wheel projections of the residues 8–27 and 36–65, containing the 
most aggregation-prone regions 14–22 and 49–57 [25]. Obviously, the positively charged amino 
acid residues of the ApoA-I N-terminal fragment could associate with the sn-2 chain of PazePC 
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extended into the aqueous phase via strong electrostatic interactions [20,29]. This may increase 
free energy of denaturation of the α-helixes and, as a consequence, reduce the fibrillization 
extent, as compared to the neat POPC vesicles. Notably, it is PazePC interaction with the residue 
R26 that could be critical for the inhibition of the 1-83/G26R aggregation by the oxidized 
phospholipids [25]. Unlike lipid vesicles, micelles are composed only of the PazePC molecules, 
resulting in the increased number of the protein-lipid electrostatic contacts on the micelle surface 
and the complete inhibition of the 1-83/G26R aggregation. Interestingly, PoxnoPC micelles 
induced a less pronounced increase in the 1-83/G26R fibrillization, compared to the lipid 
dispersions (Fig. 2B), being indicative of their potential to inhibit amyloid fibril formation by 
specific interactions with the protein at higher lipid-to-protein molar ratios, than PazePC. 
Furthermore, since the 1-83/G26R is unstructured in solution, its electrostatic interactions and 
Schiff base formation with PazePC and PoxnoPC dispersions, respectively, could result in the 
protein cross-linking, nucleation and lipid embedding into the oligomers and amyloid fibrils 
[27,35]. The above processes may lead to the experimentally observed enhancement of the 1-
83/G26R fibrillization with the concentration of lipid dispersions (Table 1). In turn, significant 
increase in the lag time of the 1-83/G26R amyloid formation in the presence of lipid vesicles 
used in this study seems to result from the lowered protein concentration on the membrane 
surface, but not due to the stabilization of the protein α-helical conformation, as was suggested 
for the lipid dispersions and micelles [25].  
 
4. Conclusions 
In conclusion, our fluorescence studies demonstrated that the kinetic parameters of the 1-
83/G26R fibrillization varied significantly with the oxPLs structure, concentration and the type 
of lipid assemblies (premicellar aggregates, micelles or lipid bilayer vesicles). Specifically, 
membrane/micelle surfaces were found to play a critical role in inhibition of the amyloid fibril 
formation, presumably due to their ability to stabilize α-helical structure of the 1-83/G26R by the 
protein-lipid electrostatic and covalent interactions. Furthermore, the increase in the lag time of 
the 1-83/G26R fibrillization induced by the oxPLs suggest that their binding to the protein 
hampered the formation of amyloid nuclei. Overall, the results obtained indicate that despite the 
involvement of the oxidative stress into pathogenesis of amyloid diseases, the oxidized 
phospholipids can be regarded as candidates for novel anti-amyloid agents. 
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Legends to figures 
 
Fig. 1. Structures of 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-
azelaoyl-sn-glycero-3-phosphocholine (PazePC) and 1-palmitoyl-2-(9'-oxononanoyl)-sn-glycero-
3-phosphocholine (PoxnoPC). 
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Fig. 2. Fibrillization kinetics of the apoA-I 1-83/G26R variant in the absence or presence of 
PazePC (A – experimental, C – fitted curves) and PoxnoPC (B – experimental, D – fitted curves) 
lipid dispersions: 1 – no lipid, 2,3,4 – correspond to protein-to-lipid molar ratios 10:1, 1:1 and 
1:10, respectively. Protein concentration was 5 µM, ThT concentration was 10 µM. PazePC and 
PoxnoPC concentrations were 0.5 µM, 5 µM and 50 µM. 
 
Fig. 3. Fibrillization kinetics of the apoA-I 1-83 (A) and 1-83/G26R (B) variants in the absence 
or presence of PazePC and PoxnoPC lipid dispersions: 1 – no lipid, 2 – PazePC, 3 – PoxnoPC. 
Protein concentration was 5 µM, ThT concentration was 10 µM. PazePC and PoxnoPC 
concentrations were 50 µM, corresponding to the protein-to-lipid molar ratio 1:10. 
 
Fig. 4. Fibrillization kinetics of the apoA-I 1-83/G26R variant in the presence of: 1 – POPC, 2 – 
POPC/PazePC (20 mol%), 3 – POPC/ PoxnoPC (20 mol%) liposomes (A – experimental, B – 
fitted curves). Protein concentration was 5 µM, ThT concentration was 10 µM. Liposome 
concentration was 2 mM, corresponding to POPC-to-apoA-I weight ratio ~ 31. 
 
Fig. 5. Schematic illustration of the model for the association between 1-83/G26R and 
POPC/PazePC (20 mol%) bilayer. The black line represents the hydrophilic-hydrophobic 
interface of the bilayer leaflet. 
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Table 1 
Kinetic parameters of amyloid formation by apoA-I 1-83 and apoA-I 1-83/G26R in the presence 
of oxidized phospholipids. 
System 
maxF , a.u. mt , h 
310k  , h-1 Lag time, h R
2
 
1-83 133 90 29
 
21 0.995 
1-83 + PazePC (1:10) - - - - - 
1-83 + PoxnoPC (1:10) 54 176 15 43 0.994 
1-83/G26R 71 19 188 8 0.997 
1-83/G26R + PazePC (1:10) - - - - - 
1-83/G26R + PazePC (1:1) 105 38 131 23 0.997 
1-83/G26R + PazePC (10:1) 55 30 115 13 0.994 
1-83/G26R + PoxnoPC (1:10) 129 35 92 13 0.994 
1-83/G26R + PoxnoPC (1:1) 290 28 119 11 0.992 
1-83/G26R + PoxnoPC (10:1) 191 34 200 24 0.997 
1-83/G26R + POPC 156 132 53 94 0.999 
1-83/G26R + POPC/PazePC(20 mol%) 110 125 36 69 0.999 
1-83/G26R + POPC/PoxnoPC(20 mol%) 158 125 42 77 0.999 
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Fig. 2D 
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Fig. 4B 
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